Compare MobilEye Global Inc (MBLY) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MobilEye Global Inc vs Viatris Inc — how do they compare? MobilEye Global Inc trades at $7.12 (market cap $6.00B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 3.3× MobilEye Global Inc's market cap, and Viatris Inc pays a 2.75% dividend while MobilEye Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MobilEye Global Inc for 15 Days and Viatris Inc for 57 Days on average.
| MBLY | VTRS | |
|---|---|---|
Market Cap | $6.00B | $20.03B |
Volume | 7,007,849 | 14,109,977 |
Sector | Consumer Cyclical | Health |
52-Week High | $15.42 | $18.27 |
52-Week Low | $6.56 | $9.74 |
Typical Hold Time | 15 Days | 57 Days |
Enterprise Value | $4.56B | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mobileye Global (MBLY) trades at $7.11, down 0.56% on the day, with a bearish technical outlook but mixed fundamental signals. The stock shows negative profitability with a net income margin of -201.49% for 2026, yet revenue grew to $2.0 billion. Recent earnings beats in Q1 and Q2 2026 contrast with a Q4 2025 miss, while analyst consensus is a 'Buy' with a $10.83 price target. News highlights ADAS momentum and a robotaxi strategy expansion, but the stock faces significant cash flow volatility.
The outlook for MBLY is cautious; while analyst optimism and revenue growth provide upside potential, persistent losses and bearish technicals pose risks. Investment opportunity hinges on execution of autonomous driving programs, but shareholders face volatility from negative earnings and high valuation multiples like EV/EBITDA of 32.34.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
